NASDAQ: ALTAltimmune Inc Stock
$8.01-0.89 (-10%)
Updated May 17, 2024
ALT Price
$8.01
Fair Value Price
$2.52
Market Cap
$567.93M
52 Week Low
$2.09
52 Week High
$14.84
P/E
-4.98x
P/B
3.28x
P/S
1,757.96x
PEG
N/A
Dividend Yield
N/A
Revenue
$410.00k
Earnings
-$92.77M
Gross Margin
100%
Operating Margin
-22,617.8%
Profit Margin
-22,626.1%
Debt to Equity
0.09
Operating Cash Flow
-$73M
Beta
0.39
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ALT Overview
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Zen Score
–
Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ALT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ALT ($8.01) is overvalued by 218.38% relative to our estimate of its Fair Value price of $2.52 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ALT ($8.01) is not significantly undervalued (218.38%) relative to our estimate of its Fair Value price of $2.52 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ALT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ALT due diligence checks available for Premium users.
Be the first to know about important ALT news, forecast changes, insider trades & much more!
ALT News
Valuation
ALT fair value
Fair Value of ALT stock based on Discounted Cash Flow (DCF)
Price
$8.01
Fair Value
$2.52
Overvalued by
218.38%
ALT ($8.01) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ALT ($8.01) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ALT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ALT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.98x
Industry
8.47x
Market
30.97x
ALT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.28x
Industry
6.01x
ALT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ALT's financial health
Profit margin
Revenue
$5.0k
Net Income
-$24.4M
Profit Margin
-487,880%
ALT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ALT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$188.4M
Liabilities
$15.4M
Debt to equity
0.09
ALT's short-term assets ($187.52M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALT's short-term assets ($187.52M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ALT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$16.4M
Investing
-$39.5M
Financing
-$261.0k
ALT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ALT vs Biotech Stocks
Altimmune Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.